scholarly journals Effects of testosterone on the lower urinary tract go beyond the prostate: New insights, new treatment options

2011 ◽  
Vol 9 (2) ◽  
pp. 147-152 ◽  
Author(s):  
Farid Saad ◽  
Aksam A. Yassin ◽  
Ahmad Haider ◽  
Louis Gooren
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract ◽  
Treatment Options ◽  
New Treatment ◽  
Lower Urinary

scholarly journals Lower Urinary Tract Neoplasia

2018 ◽  
Vol 5 (4) ◽  
pp. 96 ◽  
Author(s):  
Maureen Griffin ◽  
William Culp ◽  
Robert Rebhun
Keyword(s):  
Urinary Tract ◽  
Urinary Bladder ◽  
Lower Urinary Tract ◽  
Treatment Options ◽  
Transitional Cell ◽  
Companion Animals ◽  
Disease Process ◽  
Life Threatening ◽  
Comparative Model ◽  
Lower Urinary

Lower urinary tract neoplasia in companion animals is a debilitating and often life-threatening disease. Tumors of the bladder, urethra, and prostate often occur independently, although extension of these tumors into adjacent regions of the lower urinary tract is documented frequently. The most common lower urinary tract tumor in dogs and cats is transitional cell carcinoma (TCC). In both dogs and cats, TCC affecting the urinary bladder is generally considered to be highly aggressive with both local and metastatic disease potential, and this disease poses unique treatment challenges. Whereas much literature exists regarding the TCC disease process, treatment options, and prognosis in dogs, relatively few studies on feline TCC have been published due to the lower incidence of TCC in this species. Prostate tumors, most commonly adenocarcinomas, occur less commonly in dogs and cats but serve an important role as a comparative model for prostate neoplasia in humans. This article serves as a review of the current information regarding canine and feline lower urinary tract neoplasia as well as the relevance of these diseases with respect to their human counterparts.

The combined symptoms of male lower urinary tract: current treatment options

Urologiia ◽  
2018 ◽  
Vol 4_2018 ◽  
pp. 135-141
Author(s):  
Z.K. Gadzhieva Gadzhieva ◽  
M.A. Gazimiev Gazimiev ◽  
Yu.B. Kazilov Kazilov ◽  
V.A. Grigoryan Grigoryan ◽  
◽  
...  
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract ◽  
Treatment Options ◽  
Current Treatment ◽  
Lower Urinary

scholarly journals Fetoscopic laser valve ablation in the posterior urethral valve case with intrauterine diagnosis

2020 ◽  
Vol 28 (3) ◽  
pp. 206-211
Author(s):  
Selahattin Kumru ◽  
Serdar Kaya
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract ◽  
Urinary Tract Obstruction ◽  
Treatment Options ◽  
Posterior Urethral Valve ◽  
Fetal Ultrasonography ◽  
Lower Urinary Tract Obstruction ◽  
Urethral Valve ◽  
Lower Urinary

Objective: We aimed to present the procedure of intrauterine percutaneous fetoscopic laser valve ablation performed on a fetus diagnosed with lower urinary tract obstruction. Case(s): Bilateral hydroureteronephrosis, dilated bladder and oligo/ anhydramnios were found in the fetal ultrasonography examination of a 21-year-old pregnant woman who did not have regular follow-ups, and the lower urinary tract obstruction consistent with the posterior urethral valve was considered in the case. The patient who was found to have poor prognosis as a result of vesico synthesis carried out consecutively was informed about the follow-up and treatment options, and the posterior urethral valve ablation was performed by the percutaneous fetoscopic laser on 27 weeks of gestation. The amniotic fluid was at normal levels after the procedure, and the labor was carried out at term. The newborn with elevated postpartum creatinine was diagnosed with stage 2 renal failure, but dialysis was not required during the follow-ups. The newborn was discharged for outpatient follow-up upon the reduced creatinine levels. Conclusion: By taking the survival enhancing effect of the intrauterine intervention into account in the presence of lower urinary tract obstruction, we considered that intrauterine intervention can be an option in the cases who prefer to continue their pregnancies. The families should be informed in detail about the benefits and risks of intrauterine intervention to repair the obstruction.

scholarly journals Benign prostatic hyperplasia and lower urinary tract symptom guidelines

2013 ◽  
Vol 6 (5-S2) ◽  
pp. 130 ◽  
Author(s):  
Claus Roehrborn
Keyword(s):  
Clinical Trial ◽  
Urinary Tract ◽  
Lower Urinary Tract ◽  
Treatment Options ◽  
Clinical Trial Data ◽  
Prostatic Hyperplasia ◽  
Trial Data ◽  
Pharmacologic Treatment ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

Lower urinary tract symptoms (LUTS) are very common in men,with incidence increasing with age. Several clinical practice guidelines are available as decision-making aids for men with LUTS and the recommendations are based on the presumed etiology of the symptoms (due to obstruction, overactive bladder or a combination of the two). This review presents the various pharmacologic treatment options and summarizes key clinical trial data supporting their use.

Current pharmacological treatment options for male lower urinary tract symptoms

2013 ◽  
Vol 14 (8) ◽  
pp. 1043-1054 ◽  
Author(s):  
Frank Strittmatter ◽  
Christian Gratzke ◽  
Christian G Stief ◽  
Petter Hedlund
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Pharmacological Treatment ◽  
Lower Urinary Tract ◽  
Treatment Options ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

scholarly journals Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base

2017 ◽  
Vol 10 (2) ◽  
pp. 79-92 ◽  
Author(s):  
Mauro Gacci ◽  
Arcangelo Sebastianelli ◽  
Pietro Spatafora ◽  
Giovanni Corona ◽  
Sergio Serni ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Treatment Options ◽  
Specific Recommendation ◽  
Phosphodiesterase Type 5 Inhibitors ◽  
Voiding Symptoms ◽  
Urinary Tract Symptoms ◽  
Detailed Medical History ◽  
Lower Urinary

Storage lower urinary tract symptoms (LUTS) are characterized by an altered bladder sensation, increased daytime frequency, nocturia, urgency and urgency incontinence. Some evidence underlines the role of metabolic factors, pelvic ischemia, prostatic chronic inflammation and associated comorbidities in the pathophysiology of storage LUTS. A detailed evaluation of the severity of storage LUTS, and the concomitance of these symptoms with voiding and postmicturition symptoms, is mandatory for improving the diagnosis and personalizing treatment. A detailed medical history with comorbidities and associated risk factors, a physical examination, a comprehensive analysis of all the features of LUTS, including their impact on quality of life, and a frequency–volume chart (FVC) or bladder diary, are recommended for men with storage LUTS. Several drugs are available for the treatment of LUTS secondary to benign prostatic obstruction (BPO). Alpha-blockers (α-blockers), 5-α-reductase inhibitors and phosphodiesterase type 5 inhibitors are commonly used to manage storage LUTS occurring with voiding symptoms associated with BPO. Muscarinic receptor antagonists and Beta 3-agonists (β3-agonists) alone, or in combination with α-blockers, represent the gold standard of treatment in men with predominant storage LUTS. There is no specific recommendation regarding the best treatment options for storage LUTS after prostatic surgery.

Sign in / Sign up

Export Citation Format

Share Document